ReviewIndian heart journal
The Beta-blocker chronicle: From past principles to present practice - Implications for the Indian subcontinent.
Review in Indian heart journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-blockers have evolved from being foundational cardiovascular agents to precision therapies across diverse clinical scenarios. Their journey from early non-selective to β1-selective and vasodilatory molecules reflects advances in understanding adrenergic modulation in cardiovascular continuum. β-blockers remain integral in managing hypertension, chronic coronary syndromes, arrhythmias, and heart failure. Their pharmacodynamic attributes such as β1-selectivity, inverse agonism, sympathoinhibition, and vasodilation allow personalized use in patients with comorbidities like diabetes, asthma or chronic kidney disease. Among contemporary agents, bisoprolol and nebivolol exemplify next generation β-blockers with high β1-selectivity, favourable tolerability, and cardioprotective effects beyond blood pressure and heart rate control. Global and national guidelines recommend them for angina relief, secondary prevention post-MI, and rate control in tachyarrhythmias. In Indian context, prescribing trends highlight bisoprolol among the most prescribed β-blockers, reflecting its clinical trust and relevance. Regional experiences affirm the value of β-blockers in optimizing cardiovascular outcomes across the Indian subcontinent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.